In polypathological patients an early diagnosis of respiratory failure is often difficult. Frequently, polypathology does not allow intubation and intensive care unit (ICU) treatment with invasive mechanical ventilation (IMV). Non-invasive ventilation (NIV) and admission to respiratory intermediate care unit (RICU) may be the only option in these cases. Presepsin, a new predictive marker of systemic infection, appears particularly usefull for early diagnosis, treatment and prognosis of sepsis. 1.2. Case A 73-year-old man with a previous history of ischemic heart disease undergoing coronary artery bypass grafting (CABG), residual constrictive pericarditis, previous multiple hospitalizations for heart failure (CHF), autoimmune hemolytic anemia on chronic steroid therapy and cognitive impairment arrived to the Emergency Department (ED) in acute global respiratory failure with severe acidosis; he was normothermic, radiological imaging showed aspecific diffuse parenchymal thickening and traditional inflammatory markers (white blood cell - WBC - count and serum level of C-reactive protein - CPR - and procalcitonin - PCT) were in normal range, but blood tests revealed a marked elevation in the value of presepsin. Intensivist’s evaluation concluded for a do-not intubate (DNI) status and the patient was admitted to RICU. The combined treatment with NIV, broad-spectrum antibiotics and dopamine resulted in a progressive improvement of the clinical, laboratoristic and radiological parameters and the subsequent discharge of the patient to home in satisfactory general condition. 1.3. Conclusions Elevated presepsin level was found to be an early predictor of severe sepsis, ofter preceding other laboratory or clinical signs of infection. NIV in RICU and medical therapy allowed the successful treatment of a severe global respiratory failure in a DNI patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.